Paratek Pharmaceuticals Overview

  • Founded
  • 1996
Founded
  • Status
  • Public
  • Employees
  • 102
Employees
  • Stock Symbol
  • PRTK
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $6.80
  • (As of Friday Closing)

Paratek Pharmaceuticals General Information

Description

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. Omadacycline is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. Sarecycline is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 75 Park Plaza
  • 4th Floor
  • Boston, MA 02116
  • United States
+1 (617) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Paratek Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.80 $6.74 $2.50 - $7.27 $310M 45.6M 375K -$2.45

Paratek Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 321,678 171,267 105,316 385,783
Revenue 39,870 16,544 17,117 12,616
EBITDA (80,774) (115,660) (104,129) (83,346)
Net Income (98,896) (128,790) (112,356) (89,069)
Total Assets 198,686 251,079 300,192 163,698
Total Debt 251,995 262,823 228,959 59,186
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Paratek Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Paratek Pharmaceuticals‘s full profile, request access.

Request a free trial

Paratek Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Paratek Pharmaceuticals‘s full profile, request access.

Request a free trial

Paratek Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on te
Pharmaceuticals
Boston, MA
102 As of 2019
00000
000000 - 000 00000

00000000

do consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
000000000000000
West Conshohocken, PA
00 As of 0000
000.00
000000 - 000 000.00

00000000

e eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui offici
000000000000000
Coral Gables, FL
00 As of 0000
000.00
0000 0000-00-00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Paratek Pharmaceuticals Competitors (34)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Madrigal Pharmaceuticals Corporation West Conshohocken, PA 00 000.00 000000 - 000 000.00
00000000 000000000 Formerly VC-backed Coral Gables, FL 00 000.00 00000000 000.00
000000000(00000000 Formerly VC-backed New York, NY 000 00000 000000 - 000 00000
000 000000 00000 Private Debt Financed Bresso, Italy 0000 000.00 000000000 000.00
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000&0
You’re viewing 5 of 34 competitors. Get the full list »

Paratek Pharmaceuticals Executive Team (25)

Name Title Board Seat Contact Info
Evan Loh MD Chief Executive Officer & Board Member
Adam Woodrow Executive & President
Sarah Higgins Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Douglas Pagán Chief Financial Officer & Director
Randall Brenner Executive
You’re viewing 5 of 25 executive team members. Get the full list »

Paratek Pharmaceuticals Board Members (11)

Name Representing Role Since
Evan Loh MD Paratek Pharmaceuticals Chief Executive Officer & Board Member 000 0000
Jeffrey Stein Ph.D Self Board Member 000 0000
Kristine Peterson Paratek Pharmaceuticals Board Member 000 0000
Michael Bigham Paratek Pharmaceuticals Chairman & Board Member 000 0000
Robert Radie Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Paratek Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Paratek Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Paratek Pharmaceuticals‘s full profile, request access.

Request a free trial

Paratek Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 30-Oct-2014 000000000000000000 Pharmaceuticals
To view Paratek Pharmaceuticals’s complete acquisitions history, request access »